ruxolitinib


( Last Updated : June 9, 2022)
Generic Name:
ruxolitinib
Project Status:
Active
Therapeutic Area:
Graft versus host disease
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Jakavi
Project Line:
Reimbursement Review
Project Number:
SR0706-000
NOC Status at Filing:
Pre NOC

Details

Manufacturer Requested Reimbursement Criteria1:
For the treatment of chronic graft-versus-host disease in patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of chronic graft-versus-host disease in patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2
Call for patient/clinician input open July 12, 2021
Call for patient/clinician input closed September 03, 2021
Clarification:

- Patient input submission received from LC, LLSC, CLL Canada, Myeloma Canada, AAMAC, CMPNRF, CML Network, and CTTC
Submission received August 10, 2021
Submission accepted August 26, 2021
Clarification:

- Submission was not accepted for review on 24 Aug 2021

- Submission temporarily suspended

- Additional information has been received and the temporary suspension of the review has been lifted
Review initiated August 27, 2021
Draft CADTH review report(s) provided to sponsor for comment January 26, 2022
Deadline for sponsors comments February 04, 2022
CADTH review report(s) and responses to comments provided to sponsor March 11, 2022
Expert committee meeting (initial) March 23, 2022
Draft recommendation issued to sponsor 08-Jun-22
Draft recommendation posted for stakeholder feedback 16-Jun-22
End of feedback period 30-Jun-22

Files

Draft Recommendation